Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boston Scientific Co. stock logo
BSX
Boston Scientific
$84.02
+0.0%
$83.82
$50.26
$88.79
$123.27B0.86.10 million shs7.43 million shs
DexCom, Inc. stock logo
DXCM
DexCom
$70.48
-1.8%
$69.96
$62.34
$142.00
$27.53B1.183.91 million shs4.04 million shs
ResMed Inc. stock logo
RMD
ResMed
$242.47
-0.2%
$241.90
$138.55
$260.49
$35.59B0.691.05 million shs1.16 million shs
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$307.90
-1.6%
$301.40
$265.00
$413.70
$22.30B1.01569,893 shs966,427 shs
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boston Scientific Co. stock logo
BSX
Boston Scientific
-0.64%-3.92%+0.26%+11.79%+64.13%
DexCom, Inc. stock logo
DXCM
DexCom
-0.61%-0.94%+7.10%+2.10%-19.17%
ResMed Inc. stock logo
RMD
ResMed
-0.63%+2.31%-0.51%+13.20%+71.99%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
-1.59%+9.40%+4.40%+3.66%-1.55%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Boston Scientific Co. stock logo
BSX
Boston Scientific
4.8138 of 5 stars
3.53.00.04.23.12.52.5
DexCom, Inc. stock logo
DXCM
DexCom
4.9946 of 5 stars
4.45.00.04.73.02.53.1
ResMed Inc. stock logo
RMD
ResMed
4.4986 of 5 stars
2.31.03.34.52.71.72.5
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
4.9377 of 5 stars
3.33.03.33.22.52.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Boston Scientific Co. stock logo
BSX
Boston Scientific
2.91
Moderate Buy$93.3911.15% Upside
DexCom, Inc. stock logo
DXCM
DexCom
2.72
Moderate Buy$104.5948.39% Upside
ResMed Inc. stock logo
RMD
ResMed
2.50
Moderate Buy$225.70-6.92% Downside
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
2.67
Moderate Buy$460.3349.51% Upside

Current Analyst Ratings

Latest BSX, DXCM, RMD, and WST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/31/2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
10/25/2024
DexCom, Inc. stock logo
DXCM
DexCom
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$82.00 ➝ $86.00
10/25/2024
DexCom, Inc. stock logo
DXCM
DexCom
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$120.00 ➝ $115.00
10/25/2024
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetStrong-Buy ➝ Strong-Buy$115.00 ➝ $99.00
10/25/2024
DexCom, Inc. stock logo
DXCM
DexCom
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$115.00 ➝ $105.00
10/25/2024
DexCom, Inc. stock logo
DXCM
DexCom
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$75.00 ➝ $85.00
10/25/2024
DexCom, Inc. stock logo
DXCM
DexCom
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$90.00 ➝ $87.00
10/25/2024
DexCom, Inc. stock logo
DXCM
DexCom
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$80.00 ➝ $90.00
10/25/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$251.00 ➝ $266.00
10/25/2024
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$224.00 ➝ $232.00
10/25/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
(Data available from 10/31/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Boston Scientific Co. stock logo
BSX
Boston Scientific
$15.91B7.75$2.81 per share29.86$13.33 per share6.30
DexCom, Inc. stock logo
DXCM
DexCom
$3.95B6.96$2.00 per share35.32$5.35 per share13.17
ResMed Inc. stock logo
RMD
ResMed
$4.81B7.40$8.74 per share27.75$33.11 per share7.32
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$2.88B7.75$10.18 per share30.25$39.31 per share7.83

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Boston Scientific Co. stock logo
BSX
Boston Scientific
$1.59B$1.1968.3131.002.8712.00%16.59%9.22%1/29/2025 (Estimated)
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.6743.5135.242.2616.95%31.41%10.84%2/13/2025 (Estimated)
ResMed Inc. stock logo
RMD
ResMed
$1.02B$7.5532.1224.392.0523.15%25.53%17.59%1/22/2025 (Estimated)
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$593.40M$6.7445.6840.8423.6817.37%18.41%13.74%2/20/2025 (Estimated)

Latest BSX, DXCM, RMD, and WST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/24/2024Q1 2025
ResMed Inc. stock logo
RMD
ResMed
$2.03$2.20+$0.17$2.29$1.19 billion$1.22 billion      
10/24/2024Q3 2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$1.50$1.85+$0.35$1.85$709.62 million$746.90 million      
10/23/2024Q3 2024
Boston Scientific Co. stock logo
BSX
Boston Scientific
$0.59$0.63+$0.04$0.94$4.04 billion$4.21 billion    
8/1/2024Q4 2024
ResMed Inc. stock logo
RMD
ResMed
$2.03$2.08+$0.05$2.18$1.22 billion$1.20 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Boston Scientific Co. stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$2.120.87%+5.66%28.08%13 Years
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
$0.840.27%+5.81%12.46%31 Years

Latest BSX, DXCM, RMD, and WST Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/24/2024
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.8%11/7/202411/7/202412/12/2024
10/24/2024
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
Quarterly$0.210.25%11/13/202411/13/202411/20/2024
8/1/2024
ResMed Inc. stock logo
RMD
ResMed
quarterly$0.530.9%8/15/20248/15/20249/19/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.44
1.61
1.14
DexCom, Inc. stock logo
DXCM
DexCom
1.00
2.82
2.48
ResMed Inc. stock logo
RMD
ResMed
0.13
2.92
1.91
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.07
3.00
2.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Boston Scientific Co. stock logo
BSX
Boston Scientific
89.07%
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
ResMed Inc. stock logo
RMD
ResMed
54.98%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
93.90%

Insider Ownership

CompanyInsider Ownership
Boston Scientific Co. stock logo
BSX
Boston Scientific
0.50%
DexCom, Inc. stock logo
DXCM
DexCom
0.30%
ResMed Inc. stock logo
RMD
ResMed
0.71%
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
0.53%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Boston Scientific Co. stock logo
BSX
Boston Scientific
48,0001.47 billion1.47 billionOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600390.60 million399.53 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
9,980146.80 million145.72 millionOptionable
West Pharmaceutical Services, Inc. stock logo
WST
West Pharmaceutical Services
10,60072.42 million72.04 millionOptionable

BSX, DXCM, RMD, and WST Headlines

Recent News About These Companies

West to Participate in Upcoming Investor Conferences
William Blair Analysts Decrease Earnings Estimates for WST
West Pharmaceutical Services, Inc. stock logo
William Blair Brokers Decrease Earnings Estimates for WST
Jefferies Keeps Their Buy Rating on West Pharmaceutical Services (WST)
West Pharmaceutical Services Raises FY24 Guidance - Update

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Boston Scientific logo

Boston Scientific

NYSE:BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
West Pharmaceutical Services logo

West Pharmaceutical Services

NYSE:WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. This segment also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. The company serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.